Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly EBT Margin of 1439.7% for Q1 2026, down 55098.0% year-over-year from N/an in Q1 2025, and up 57.79% quarter-over-quarter from 3411.01% in Q4 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported EBT Margin for 8 consecutive years, with 1439.7% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 55098.0% year-over-year to 1439.7%; the TTM figure through Mar 2026 stood at 2241.92% (down 121204.0% YoY), while the FY2025 annual figure was 1912.45%, down 85483.0% from the prior year.
- EBT Margin grew to 1439.7% in Q1 2026 per KYMR's latest filing, from 3411.01% in the prior quarter.
- Across five years, EBT Margin topped out at 143.96% in Q4 2023 and bottomed at 12394.21% in Q3 2025.
- Historically, EBT Margin has averaged 2311.24% across 5 years, with a median of 1187.89% in 2023.
- On a YoY basis, EBT Margin climbed as much as 94891 bps in 2025 and fell as far as 647855 bps in 2025.
- Kymera Therapeutics' EBT Margin stood at 239.74% in 2022, then surged by 40 bps to 143.96% in 2023, then plunged by 659 bps to 1092.39% in 2024, then plunged by 212 bps to 3411.01% in 2025, then soared by 58 bps to 1439.7% in 2026.
- Business Quant data shows KYMR's EBT Margin at 1439.7% in Q1 2026, 3411.01% in Q4 2025, and 12394.21% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -116.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -116.44% |
| Mar 31, 2026 | -245.06% |
| Dec 31, 2025 | -3,414.15% |
| Sep 30, 2025 | -3,350.90% |
| Jun 30, 2025 | -737.76% |
| Mar 31, 2025 | -337.10% |
| Dec 31, 2024 | -1,092.97% |
| Sep 30, 2024 | -1,929.54% |
| Jun 30, 2024 | -198.78% |
| Mar 31, 2024 | -562.85% |
| Dec 31, 2023 | -40.44% |
| Sep 30, 2023 | -1,217.22% |
| Jun 30, 2023 | -263.01% |
| Mar 31, 2023 | -479.41% |
| Dec 31, 2022 | -239.72% |
| Sep 30, 2022 | -470.30% |
| Jun 30, 2022 | -354.79% |
| Mar 31, 2022 | -384.27% |
| Dec 31, 2021 | -222.88% |
| Sep 30, 2021 | -141.16% |